Contemporary Oncology (Jan 2021)

Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study

  • Lobna A. Abdelaziz,
  • Heba F. Taha,
  • Magid M. Ali,
  • Marwa I. Abdelgawad,
  • Amira Elwan

DOI
https://doi.org/10.5114/wo.2020.102802
Journal volume & issue
Vol. 24, no. 4
pp. 221 – 228

Abstract

Read online

No abstracts available.

Keywords